Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_assertion type Assertion NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_head.
- NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_assertion description "[However, recent reports of myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) developing after treatment with immunosuppressants and G-CSF has raised concern over the use of this agent in patients with aplastic anemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_provenance.
- NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_assertion evidence source_evidence_literature NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_provenance.
- NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_assertion SIO_000772 14607763 NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_provenance.
- NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_assertion wasDerivedFrom befree-2016 NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_provenance.
- NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_assertion wasGeneratedBy ECO_0000203 NP419933.RAp0G3rAqrfP5rp1jI2JcRxhkIAlUu4MCVcPn4d_riFOk130_provenance.